Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Halogenated hydrocarbon doai
Reexamination Certificate
2008-01-16
2011-11-29
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Halogenated hydrocarbon doai
C514S277000, C514S290000, C546S079000
Reexamination Certificate
active
08067473
ABSTRACT:
Disclosed are methods and compositions useful in identifying an E3 ubiquitin ligase inhibitor and modulating cell growth, comprising contacting a cell with an effective amount of an inhibitor of an E3 ubiquitin ligase, and contacting the cell with an effective amount of a topoisomerase inhibitor, wherein the treatment with the E3 ubiquitin ligase inhibitor and topoisomerase inhibitor modulates cell growth in comparison to a cell treated with the topoisomerase inhibitor alone. The present invention further provides methods for identifying and making an E3 ubiquitin ligase inhibitor.
REFERENCES:
patent: 2004/0180889 (2004-09-01), Suto et al.
patent: WO 03/059290 (2003-07-01), None
patent: WO 2008/087643 (2008-07-01), None
PCT International Search Report issued Dec. 23, 2008 in connection with PCT/IL2008/000073, filed Jan. 16, 2008.
Fickentscher, Kurt et al. (1980) “Synthesis and Teratogenic . . . Indane-1,3-diones” Archiv Der Pharmazie (Weinheim, Germany) 313(6), 481-7 (including English-language abstract).
Written Opinion of International Searching Authority issued on Jul. 16, 2009 in connection with PCT/IL2008/000073, filed on Jan. 16, 2008.
PCT International Preliminary Report on Patentability issued on Jul. 21, 2009 in connection with PCT/IL2008/000073, filed on Jan. 16, 2008.
Gurrieri, C., et al. (2004) “Loss of the tumor suppressor PML in human cancers of multiple histologic origins.” J Natl Cancer Inst. 96(4):269-79.
Berezovska, O.P., et al. (2006) “Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.” Cell Cycle, 5:1886-901 (Exhibit 1).
Cao, R., et al. (2005) “Role of Bmi-1 and Ring1A in H2A ubiquitylation and HOX gene silencing.” Mol. Cell, 20:845-54 (Exhibit 2).
de Napoles, M., et al., (2004) “Polycomb group proteins Ring1A/B link ubiquitylation of histone H2A to heritable gene silencing and X inactivation.” Dev. Cell, 7:663-76 (Exhibit 3).
Fang, J., et al., (2004) “Ring1b-mediated H2A ubiquitination associates with inactive X chromosomes and is involved in initiation of X inactivation.” J Biol. Chem., 279:52812-5 (Exhibit 4).
Gambacorta, M., et al. (1996) “Heterogeneous nuclear expression of the promyelocytic leukemia (PML) protein in normal and neoplastic human tissues.” Am. J Pathol., 149(6):2023-35 (Exhibit 5).
He, D., et al. (1997) “Adenovirus-mediated expression of PML suppresses growth and tumorigenicity of prostate cancer cells.” Cancer Res., 57(10):1868-72 (Exhibit 6).
He, D., et al. (2003) “Overexpression of the promyelocytic leukemia gene suppresses growth of human bladder cancer cells by inducing G1 cell cycle arrest and apoptosis.” Chin. Med. J (Engl), 116(9):1394-8 (Exhibit 7).
Hernandez-Munoz, I., et al., (2005) “Stable X chromosome inactivation involves the PRC1 Polycomb complex and requires histone MACROH2A1 and the CULLIN3/SPOP ubiquitin E3 ligase.” PNAS, 102:7635-40 (Exhibit 8).
Koken, M.H., et al. (1995) “The PML growth-suppressor has an altered expression in human oncogenesis.” Oncogene, 10(7):1315-24, (Abstract Only), (Exhibit 9).
Le, X.F., et al. (1998) “Recombinant PML adenovirus suppresses growth and tumorigenicity of human breast cancer cells by inducing G1 cell cycle arrest and apoptosis.” Oncogene, 16(14):1839-49 (Exhibit 10).
Liu, L. et al., (2006) “Loss of the human polycomb group protein BMI1 promotes cancer-specific cell death.” Oncogene, 25:4370-5 (Exhibit 11).
Melnick, A. and J.D. Licht, (1999) “Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia.” Blood, 93(10):3167-215 (Exhibit 12).
Piazza, F. et al. (2001) “The theory of APL.” Oncogene, 20(49):7216-22 (Exhibit 13).
Sasaki, M., et al., (2006) “Decreased expression of Bmil is closely associated with cellular senescence in small bile ducts in primary biliary cirrhosis.” Am. J Pathol., 169:831-45 (Exhibit 14).
Son, S.H., et al. (2004) “Promyelocytic leukemia protein-induced growth suppression and cell death in liver cancer cells.” Cancer Gene Ther., 5:5 (Exhibit 15).
Wang, H., et al. (2004) “Role of histone H2A ubiquitination in Polycomb silencing.” Nature, 431:873-8 (Exhibit 16).
Wei, J. et al. (2006) “Role of Bmil in H2A ubiquitylation and Hox gene silencing.” J Biol. Chem., 21:22537-44 (Exhibit 17).
Yu, J.H., et al. (2004) “Restoration of promyelocytic leukemia protein-nuclear bodies in neuroblastoma cells enhances retinoic acid responsiveness.” Cancer Res., 64(3):928-33 (Exhibit 18); and.
Zhang, P., et al. (2000) “Lack of expression for the suppressor PML in human small cell lung carcinoma.” Int. J Cancer, 85(5):599-605 (Exhibit 19).
Alchanati Iris
Erez Omri
Nakache Philippe
Carter Kendra D
Cooper & Dunham LLP
Padmanabhan Sreeni
Teva Pharmaceutical Industries Ltd.
White John P.
LandOfFree
Methods for enhancing the therapeutic efficacy of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for enhancing the therapeutic efficacy of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for enhancing the therapeutic efficacy of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4294589